SynAct Pharma

In SynAct’s leading clinical program, resomelagon (AP1189) is used as an add-on to first-line therapy with MTX for the treatment of RA. Adding an extra layer of protection and ensuring exclusivity also in the US for this combination treatment, is central to the strategy to fortify SynAct’s intellectual property rights with respect to resomelagon (AP1189).

The US patent, when issued, can be enforced at least until 2040. The patent complements the recently issued US patent US 12,239,63 covering the crystal form of the specific resomelagon (AP1189) salt used in the clinic, and further complements also the patents issued and applications being actively prosecuted in a number of jurisdictions throughout the world.

“A strong patent portfolio, which ensures exclusivity in key markets like the US, potentially has a very big value for us and our potential partners,” said Jeppe Øvlesen, CEO at SynAct. “A patent on the combination treatment of RA with resomelagon and one of the most widely used drugs for RA, such as MTX, is certainly consolidating our position”.

In brief, a “Notice of Allowance” means that the USPTO intends to issue a US patent based on the patent application as currently on file and an Issue Notification and resulting US patent will be issued by the USPTO when all formalities are adhered to.